ArundathyNirmalini(Pandite)Bartlett PanditeMD

Hematology • Chapel Hill, NC

Physician

Join to view full profile

Are you Dr. Bartlett Pandite?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
121 Macnider Building
University Of North Carolina Department Of Medicine
Chapel Hill, NC 27599
Phone+1 919-843-5996

Fax+1 919-966-5775

Summary

Dr. Arundathy (Pandite) Bartlett Pandite, MD is a hematologist in Chapel Hill, North Carolina. She is currently licensed to practice medicine in North Carolina and Florida.

Education & Training

St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
Univ Liverpool- Fac MedClass of 1983

Certifications & Licensure

NC State Medical License 2007 - 2025
FL State Medical License 1997 - 2017
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

289 citations
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory J. Riely
The Lancet. Oncology. 2016-05-01
23 citations
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
David Goldstein, Jonathan E. Rosenberg, Robert A. Figlin, Raymond R. Townsend, Lauren McCann
European Journal of Cancer. 2016-01-01
44 citations
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer pa...
Thomas Powles, Sergio Bracarda, Mei Chen, Elliot Norry, Natalie Compton
European Journal of Cancer. 2015-07-01

Press Mentions

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) & TP53 Mutant AML PatientsJune 14th, 2024
Key Takeaways from Phase 1B Trial of SL-172154 in Frontline HR-MDS and TP53m AMLMay 14th, 2024